Fig. 6.
A patient with R/R B-ALL obtained MRD negativity twice after two round infusions of nU-CAR-T19 cells. a Major treatment progress before and after the infusion of nU-CAR-T19 cells. The patient received fludarabine (Flu, 25 mg/m2, D-6 to D-4), cyclophosphamide (CTX, 500 mg/m2, D-6 to D-5), and etoposide (VP-16, 100 mg/day, D-5 to D-4) and TBI (2 Gy/time, D-6 to D-4). Tumor burden was evaluated through bone marrow biopsy (a) at the D-1, every week in 1 and 2 months after nU-CAR-T19 cell infusion. MRD was negative at 14 days and again positive at 56 days after the first infusion of nU-CAR-T19 cells. Then, patient 7 achieved negative MRD after receiving the second infusion of the same bath nU-CAR-T19 cells (D66-67) for 7 days and later accepted the allo-HSCT. b Dynamic changes in CAR persistence and CD19+ B cells in vivo after infusion of nU-CAR-T19 cells. b Changes in live function in vivo after the first infusion of nU-CAR-T19 cells. d Dynamic changes in cytokine levels in vivo after the infusion of nU-CAR-T19 cells. e Dynamic changes in FERR level in vivo after the infusion of nU-CAR-T19 cells. f Dynamic changes in the inflammation index in vivo after the infusion of nU-CAR-T19 cells